Results 261 to 270 of about 830,619 (333)

Computational fluid dynamic modeling of the lymphatic system: a review of existing models and future directions. [PDF]

open access: yesBiomech Model Mechanobiol
Jayathungage Don TD   +5 more
europepmc   +1 more source

Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity

open access: yesAdvanced Science, EarlyView.
A tumor‐adhesive chitosan‐derived immune agonist TACTIC is developed for strong and durable anti‐tumor immunity. The immune agonist exhibits multi‐targets and modulates both tumor cell immunogenicity and pro‐inflammatory responses in immune cells, thereby potentiating the therapeutic efficacy of clinical radiotherapy.
Huilan He   +8 more
wiley   +1 more source

A Porphyrin Nanomaterial for Photoimmunotherapy for Treatment of Melanoma

open access: yesAdvanced Science, EarlyView.
The TPC@OVA NPs are developed as dual‐functional nanomaterials combining phototherapy and immunotherapy for melanoma treatment. This system effectively ablates primary tumors, induces immunogenic cell death, promotes dendritic cell maturation, and enhances T cell activation.
Zhuang Fan   +6 more
wiley   +1 more source

Connecting the Dots: The Cerebral Lymphatic System as a Bridge Between the Central Nervous System and Peripheral System in Health and Disease. [PDF]

open access: yesAging Dis
Zhao H   +20 more
europepmc   +1 more source

Tumor Microenvironment Triggered In Situ Coagulation of Supramolecularly Engineered Platelets for Precise Tumor Embolization

open access: yesAdvanced Science, EarlyView.
Occlusion of tumor blood vessels represents a promising yet challenging approach in cancer treatment. Herein, supramolecularly engineered platelets conjugated with morphology‐transformable nanoparticles is developed for precise tumor embolization. The engineered platelets actively accumulate at tumor sites following induced blood vessel injury.
Junyan Li   +9 more
wiley   +1 more source

Reshape the Fates of Treg and CD8+T Cells Through IL‐2Rα by Synergizing Divergent Receptor‐Biased IL‐2 PEGylates

open access: yesAdvanced Science, EarlyView.
This study presents receptor‐biased IL‐2 PEGylates that selectively modulate IL‐2 receptor subunit interactions to enhance CD8⁺ T cell antitumor activity while curbing Treg activation and endothelial toxicity. The combined not‐α and not‐β variants balance immune stimulation and prevent T cell exhaustion, offering a novel, fine‐tuned approach for ...
Jiaqi Sun   +23 more
wiley   +1 more source

Reprogramming the Tumor Immune Microenvironment with ICAM‐1‐Targeted Antibody‒Drug Conjugates and B7‐H3‐CD3 Bispecific Antibodies

open access: yesAdvanced Science, EarlyView.
Reprogramming the tumor immune microenvironment is crucial for transforming immune “cold” tumors into “hot” inflammatory tumors. The investigation reveals that the combination of ICAM‐1‐Dxd with B7‐H3‐CD3 bispecific antibodies not only demonstrates significant inhibitory effects on tumor growth and metastasis but also plays a vital role in ...
Shoubing Zhou   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy